Future prospects in anti-platelet therapy: A review of potential P2Y12 and thrombin receptor antagonists

Recent Patents on Cardiovascular Drug Discovery

Volumn 3, Issue 3, 2008, Pages 194-200

  Norgard, Nicholas B ^a   Abu Fadel, Mazen ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Anti platelet pharmacotherapy; Atherothrombosis; P2Y12 receptor antagonists; Platelets; Thrombin receptor antagonists

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATE DERIVATIVE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARC 69931MX; CANGRELOR; CLOPIDOGREL; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; SCH 530348; THROMBIN RECEPTOR ANTAGONIST; TICAGRELOR; TICLOPIDINE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ATHEROSCLEROTIC PLAQUE; ATHEROTHROMBOSIS; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; PATENT; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

ADENOSINE MONOPHOSPHATE; ANIMALS; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; RECEPTORS, THROMBIN; THIOPHENES; THROMBOSIS;

EID: 58149179555     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489008786264005     Document Type: Review

References (26)

1. Budaj A, Yusuf S, Mehta SR, et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 2002; 106 (13): 1622-1626.
2. Martorell L, Martínez-González J, Rodriguez C, Gentile M, Calvayrac O, Badimon L. Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb Haemost 2008; 99(2): 305-315.
3. van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 2005; 31(2): 195-204.
4. Daví G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357(24): 2482-2494.
5. Gachet C, Léon C, Hechler B. The platelet P2 receptors in arterial thrombosis. Blood Cells Mol Dis 2006; 36(2): 223-227.
6. Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005; 31(2): 174-183.
7. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348(9038): 1329-1339.
8. King S, Hirshfeld J, Jacobs A, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008; 117(2): 261-295.
9. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50 (19): 1822-1834.
10. Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111(25): 3366-3373.
11. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007; 116(25): 2923-2932.
12. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357(20): 2001-2015.
13. Fung, C.Y.E., Fung, K.P., Mahaut-Smith, M.: GB2439923 (2008).
14. Lam, P.Y.S., Clark, C.G.: WO08048981 (2008).
15. Greenbaum AB, Grines CL, Bittl JA, et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 2006; 151(3): 689.e1-689.e10.
16. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 2002; 13(7): 407-413.
17. Steinhubl S, Oh JJ, Oestreich JH, Ferraris S. Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect. Thromb Res 2008; 121: 527-534.
18. Chi, L., Choi, C., Geyer, A.G., Kennedy, R.M., Pfefferkorn, J.A., Winters, R.T.: WO08023235 (2008).
19. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007; 50(19): 1844-1851.
20. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27(9): 1038-1047.
21. Serebruany VL. Dyspnoea after AZD6140: Safety first? Eur Heart J 2006; 27(12): 1505-1506.
22. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50(19): 1852-1856.
23. Zhang, H.C., Maryanoff, B.E., Ye, H., Chen, C.: WO08054796 (2008).
24. Husted S. New developments in oral antiplatelet therapy. Eur Heart J Suppl 2007; 9(Suppl D): D20-D27.
25. Moliterno DJ, Jennings L, Becker RC, et al. On behalf of the TRA-PCI Investigators. Results of a multinational randomized, double-blind, placebo-controlled study of a novel thrombin receptor antagonist SCH 530348 in percutaneous coronary intervention. J Am Coll Cardiol 2007; 49: 2402-2409.
26. Chackalamannil, S., Wang, Y., Thiruvengadam, T.K., Zavialov, I.A., Li, T.: WO08060372 (2008).